XML 37 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (USD $)
Jun. 30, 2012
Sep. 30, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 2,282,641 $ 7,507,389
Other receivables 677,447 1,608,382
Prepaid expenses and other current assets 432,379 110,818
Marketable securities 108,965 634,585
Note receivable, net 2,401,602  
TOTAL CURRENT ASSETS 5,903,034 9,861,174
PROPERTY AND EQUIPMENT    
Computers, office equipment and furniture 508,613 285,266
Research equipment 3,409,693 3,515
Software 105,916 77,020
Leasehold improvements 2,762,737  
Property, Plant and Equipment, Gross, Total 6,786,959 365,801
Less: Accumulated depreciation and amortization (1,421,170) (340,364)
PROPERTY AND EQUIPMENT, NET 5,365,789 25,437
OTHER ASSETS    
Rent deposit 34,891  
Patents and other intangible assets, net 4,685,063 1,731,211
Note Receivable, net    2,272,868
Derivative assets 312,250 161,125
Investment in Nanotope Inc., equity basis    1,649,748
Investment in Leonardo Biosystems Inc., at cost 187,000 187,000
TOTAL OTHER ASSETS 5,219,204 6,001,952
TOTAL ASSETS 16,488,027 15,888,563
CURRENT LIABILITIES    
Accounts payable 994,372 576,809
Accrued expenses 1,022,734 864,511
Accrued payroll and benefits 1,051,079 195,649
Deferred revenue 71,875  
Derivative liabilities 869,766 944,980
Capital lease obligation 213,196  
Other current liabilities 1,592,394  
TOTAL CURRENT LIABILITIES 5,815,416 2,581,949
LONG-TERM LIABILITIES    
Note payable, net of current portion 793,513 606,786
Capital lease obligation, net of current portion 1,336,764  
Other non-current liabilities 93,731 135,660
TOTAL LONG-TERM LIABILITIES 2,224,008 742,446
Commitments and contingencies      
STOCKHOLDERS' EQUITY    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value; 145,000,000 shares authorized; 11,310,816 and 8,642,286 shares issued and outstanding as of June 30, 2012 and September 30, 2011, respectively 106,086 86,423
Additional paid-in capital 139,943,181 127,476,435
Subscription receivable (1,000,000) (900,000)
Accumulated deficit during the development stage (129,683,999) (113,871,752)
Total Arrowhead Research Corporation stockholders' equity 9,365,268 12,791,106
Noncontrolling interest (916,665) (226,938)
TOTAL STOCKHOLDERS' EQUITY 8,448,603 12,564,168
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 16,488,027 $ 15,888,563